Bridget O’Keeffe

979 total citations
13 papers, 738 citations indexed

About

Bridget O’Keeffe is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Bridget O’Keeffe has authored 13 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Bridget O’Keeffe's work include Renal cell carcinoma treatment (6 papers), Heat shock proteins research (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Bridget O’Keeffe is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Heat shock proteins research (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Bridget O’Keeffe collaborates with scholars based in United States, France and Brazil. Bridget O’Keeffe's co-authors include Gary L. Firestone, Anita C. Maiyar, Brian Kim, Meredith L. Leong, Sharleen Zhou, Yick W. Fong, Dan Chen, Qiang Zhou, Nizar M. Tannir and Neeraj Agarwal and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Bridget O’Keeffe

13 papers receiving 725 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bridget O’Keeffe United States	10	528	118	93	90	85	13	738
Nils Becker United States	13	526 1.0×	128 1.1×	183 2.0×	62 0.7×	80 0.9×	16	1.2k
Huanchun Zhang United States	13	470 0.9×	65 0.6×	138 1.5×	34 0.4×	38 0.4×	20	672
Shinya Iida Japan	16	338 0.6×	135 1.1×	87 0.9×	78 0.9×	13 0.2×	47	750
Jin K. Kim United States	13	431 0.8×	287 2.4×	143 1.5×	109 1.2×	129 1.5×	26	1.1k
Enrica Bellesia Italy	13	436 0.8×	107 0.9×	136 1.5×	70 0.8×	15 0.2×	13	768
Steve Mohr France	9	361 0.7×	118 1.0×	156 1.7×	136 1.5×	83 1.0×	12	724
Peer W. F. Karmaus United States	18	502 1.0×	186 1.6×	115 1.2×	54 0.6×	45 0.5×	38	1.4k
F. Russo-Marie France	17	584 1.1×	44 0.4×	68 0.7×	98 1.1×	108 1.3×	32	998
Yifei Zhu China	17	430 0.8×	133 1.1×	165 1.8×	69 0.8×	19 0.2×	46	787

Countries citing papers authored by Bridget O’Keeffe

Since Specialization

Citations

This map shows the geographic impact of Bridget O’Keeffe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bridget O’Keeffe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bridget O’Keeffe more than expected).

Fields of papers citing papers by Bridget O’Keeffe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bridget O’Keeffe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bridget O’Keeffe. The network helps show where Bridget O’Keeffe may publish in the future.

Co-authorship network of co-authors of Bridget O’Keeffe

This figure shows the co-authorship network connecting the top 25 collaborators of Bridget O’Keeffe. A scholar is included among the top collaborators of Bridget O’Keeffe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bridget O’Keeffe. Bridget O’Keeffe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Telli, Melinda L., Bianca Devitt, Katharine Cuff, et al.. (2022). Abstract OT2-01-03: Trial in progress: Phase 2 study of intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO™) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (KEYNOTE-890/OMS-I141). Cancer Research. 82(4_Supplement). OT2–1. 2 indexed citations

Tannir, Nizar M., Neeraj Agarwal, Sumanta K. Pal, et al.. (2020). PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 38(6_suppl). TPS763–TPS763. 16 indexed citations

Tannir, Nizar M., Neeraj Agarwal, Sumanta K. Pal, et al.. (2019). A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.. Journal of Clinical Oncology. 37(15_suppl). TPS4595–TPS4595. 3 indexed citations

Tannir, Nizar M., Neeraj Agarwal, Nancy A. Dawson, et al.. (2019). CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology. 37(7_suppl). TPS682–TPS682. 9 indexed citations

Tannir, Nizar M., Robert J. Motzer, Neeraj Agarwal, et al.. (2018). CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.. Journal of Clinical Oncology. 36(15_suppl). TPS4601–TPS4601. 17 indexed citations

McKinnell, James A., Lynn Connolly, Adrian M. Jubb, et al.. (2017). Improved Outcomes with Plazomicin (PLZ) Compared with Colistin (CST) in Patients with Bloodstream Infections (BSI) Caused by Carbapenem-resistant Enterobacteriaceae (CRE): Results from the CARE Study. Open Forum Infectious Diseases. 4(suppl_1). S531–S531. 26 indexed citations

Tolaney, Sara M., Hovav Nechushtan, Patrick Schöffski, et al.. (2016). Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Breast Cancer Research and Treatment. 160(2). 305–312. 33 indexed citations

Spoerke, Jill M., Vicky Makker, Carol Aghajanian, et al.. (2015). Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer. Molecular Cancer Therapeutics. 14(7_Supplement). A03–A03. 2 indexed citations

Powles, Thomas, Stéphane Oudard, Bernard Escudier, et al.. (2014). A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. Journal of Clinical Oncology. 32(15_suppl). 4525–4525. 17 indexed citations

10.

O’Keeffe, Bridget, et al.. (2013). The serum- and glucocorticoid-induced protein kinase-1 (Sgk-1) mitochondria connection: Identification of the IF-1 inhibitor of the F1F0-ATPase as a mitochondria-specific binding target and the stress-induced mitochondrial localization of endogenous Sgk-1. Biochimie. 95(6). 1258–1265. 18 indexed citations

11.

Firestone, Gary L., et al.. (2003). Stimulus-Dependent Regulation of Serum and Glucocorticoid Inducible Protein Kinase (SGK) Transcription, Subcellular Localization and Enzymatic Activity. Cellular Physiology and Biochemistry. 13(1). 1–12. 229 indexed citations

12.

Leong, Meredith L., Anita C. Maiyar, Brian Kim, Bridget O’Keeffe, & Gary L. Firestone. (2003). Expression of the Serum- and Glucocorticoid-inducible Protein Kinase, Sgk, Is a Cell Survival Response to Multiple Types of Environmental Stress Stimuli in Mammary Epithelial Cells. Journal of Biological Chemistry. 278(8). 5871–5882. 213 indexed citations

13.

O’Keeffe, Bridget, Yick W. Fong, Dan Chen, Sharleen Zhou, & Qiang Zhou. (2000). Requirement for a Kinase-specific Chaperone Pathway in the Production of a Cdk9/Cyclin T1 Heterodimer Responsible for P-TEFb-mediated Tat Stimulation of HIV-1 Transcription. Journal of Biological Chemistry. 275(1). 279–287. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact